Chemoradiotherapy After Surgery for Gastric Cancer Shows Similar Outcomes to Post-Operative Chemotherapy
Phase III trial finds no significant difference in overall survival
ESMO Media Releases
Anti-PD-L1 Immunotherapy Shows Response in Microsatellite-Stable Metastatic Colorectal Cancer in Combination with MEK Inhibition
Phase I trial achieves partial responses and is well tolerated
EMA ESMO Workshop: Optimising the use of single arm trials in cancer drug development
The European Medicines Agency (EMA) and the European Society for Medical Oncology (ESMO) will host a workshop on single-arm trials (SATs) at the EMA headquarters in London, UK, on June 30th 2016.
ESMO Launches First Leaders Generation Programme
A total of 15 oncologists from 12 European countries* have been chosen to participate in the first ESMO Leaders Generation Programme designed to develop the careers of oncology’s future leaders.
From Disease Treatment to Patient Care
Nearly 2,900 abstracts were submitted for inclusion within the ESMO 2016 Congress, marking a 70% increase over the past six years and confirming the ESMO Congress as the leading oncology event in Europe...
Studies Confirm Benefit of Plasma Genotyping to Predict Treatment Benefit in Patients with Non-Small-Cell Lung Cancer
The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland
Patients with EGFR Expressing Non-Small-Cell Lung Cancer Benefit Most from Necitumumab Added to Chemotherapy
Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland
Press Statement ESMO Welcomes Final Version of European Data Protection Regulation
Press Statement: ESMO Welcomes Final Version of European Data Protection Regulation
Immunotherapy With Live Bacterium Improves Response Rate in Malignant Pleural Mesothelioma
Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and 59% response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland
Osimertinib Given as First-line Treatment May Alter Biology of EGFR-Mutated Non-Small-Cell Lung Cancer
Third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is effective in the first-line treatment of EGFR mutated non-small-cell lung cancer (NSCLC), according to a late-breaking abstract presented at the European Lung Cancer Conference (ELCC) 2016
Heine H. Hansen Award Goes to Suresh Senan
The award will be presented at the European Lung Cancer Conference (ELCC) 2016, held 13 to 16 April in Geneva, Switzerland.
Back to the Essence of Medical Treatment in Oncology
The latest article to appear on ESMO Open highlights ESMO’s hope that the 2015 WHO Model List of Essential Medicines (EML) will empower oncologists and advocates to demand routine availability of the medicines considered essential to guarantee quality care of cancer patients